恩替卡韦和阿德福韦酯片治疗慢性乙型病毒性肝炎的临床比较

Clinical Comparison of Entecavir and Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B

目的分析恩替卡韦和阿德福韦酯片治疗慢性乙型病毒性肝炎的临床疗效。方法选择该院自2014年1月—2017年11月收治的58例慢性乙型病毒性肝炎患者,将其随机分为2组,对照组和观察组,每组29例。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合阿德福韦酯治疗,对比两组治疗效果。结果观察组治疗后的TBil(29.07±14.93)μmol/L、AST(47.09±13.82)U/L、ALB(41.09±2.97)g/L与对照组比较差异有统计学意义(t=4.885、5.392、4.699,P<0.05)。观察组HBV-DNA、HBeAg阴转率,ALT复常率分别为82.76%、86.21%、89.66%与对照组对比差异有统计学意义(χ~2=4.681、4.223、4.583,P<0.05)。具体表现为观察组HBV-DNA、HBV-DNA、HBeAg转阴率及及ALT复常率均较高。结论慢性乙型病毒性肝炎患者采用恩替卡韦联合阿德福韦酯治疗,疗效显著,值得在临床上使用。

Objective To analyze the clinical efficacy of entecavir and adefovir dipivoxil in the treatment of chronic hepatitis B.Methods A total of 58 patients with chronic hepatitis B admitted to the hospital from January 2014 to November 2017 were randomly divided into two groups,the control group and the observation group,with 29 cases in each group.Entecavir was given to the control group,and entecavir plus adefovir dipivoxil was given to the observation group.Results After treatment,TBil(29.07±14.93)μmol/L,AST(47.09±13.82)U/L,and ALB(41.09±2.97)g/L were significantly different from the control group(t=4.885,5.392,4.699,P<0.05).The HBV-DNA,HBeAg negative conversion rate and ALT recurrence rate in the observation group were 82.76%,86.21%,and 89.66%,respectively.Compared with the control group,the difference was significant(χ^2=4.681,4.223,4.583,P<0.05).The specific performance was higher in the observation group HBV-DNA,HBV-DNA,HBeAg negative rate and ALT recurrence rate.Conclusion Patients with chronic hepatitis B treated with entecavir and adefovir dipivoxil have significant curative effect and are worthy of clinical use.